Trevi Therapeutics, Inc. is a late stage biotechnology company focused on developing Nalbuphine ER for chronic pruritus (itch).

Trevi Therapeutics Selected to Exhibit Poster at 2014 Annual Meeting of the American College of Clinical Pharmacology
Title of Abstract: Pharmacokinetics of Nalbuphine Hydrochloride Extended Release Tablets in Hemodialysis and Healthy Subjects following Multiple Escalating Oral Doses
Trevi Therapeutics Announces Initiation of a Pivotal Study of Nalbuphine ER in Uremic Pruritus
Study will enroll 360 patients in the United States and Europe